Marlene Braz (Fundação Oswaldo Cruz (Doctorate)): Publications

More details

Fundação Oswaldo Cruz

Alumnus

Areas of Specialization

Value Theory

Science, Logic, and Mathematics

Areas of Interest

Value Theory

Science, Logic, and Mathematics

62

Ethical issues related to the access to orphan drugs in Brazil: the case of mucopolysaccharidosis type I
with Raquel Boy, Ida V. D. Schwartz, Bárbara C. Krug, Luiz C. Santana-da-Silva, Carlos E. Steiner, Angelina X. Acosta, Erlane M. Ribeiro, Marcial F. Galera, and Paulo G. C. Leivas

Journal of Medical Ethics 37 (4): 233-239. 2011.

Mucopolysaccharidosis type I (MPS I) is a rare lysosomal storage disorder treated with bone marrow transplantation or enzyme replacement therapy with laronidase, a high-cost orphan drug. Laronidase was approved by the US Food and Drug Administration and the European Medicines Agency in 2003 and by the Brazilian National Health Surveillance Agency in 2005. Many Brazilian MPS I patients have been receiving laronidase despite the absence of a governmental policy regulating access to the drug. Epide…Read more
Mucopolysaccharidosis type I (MPS I) is a rare lysosomal storage disorder treated with bone marrow transplantation or enzyme replacement therapy with laronidase, a high-cost orphan drug. Laronidase was approved by the US Food and Drug Administration and the European Medicines Agency in 2003 and by the Brazilian National Health Surveillance Agency in 2005. Many Brazilian MPS I patients have been receiving laronidase despite the absence of a governmental policy regulating access to the drug. Epidemiological and treatment data concerning MPS I are scarce. This study aims to present a demographic profile of Brazilian patients with MPS I, describe the routes of access to laronidase in Brazil, and discuss associated ethical issues relating to public funding of orphan drugs

Biomedical Ethics Drugs